Chromocell Therapeutics Corp.
We are a Phase 1 clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. (Incorporated in Delaware) Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. […]
October 16, 2023 Read More